Logo for Craif

Meet an Unreasonable Venture


Realising a society where people can live out their natural lives.

Photo of Ryuichi Onose

Ryuichi Onose

Cofounder & CEO at Craif

More about Ryuichi »
Employees 51–100
Headquarters Tokyo, Japan
Craif is a molecular diagnostics company harnessing the power of miRNA and machine learning to develop an early detection classifier. Their proprietary miRNA platform and sampling technology enable the capture of low-expression RNA, facilitating the development of assays that accurately predict early-stage cancer. In 2022, Craif launched its miSignal multi-cancer early detection assay in Japan, covering seven cancer types (pancreatic, ovarian, oesophageal, lung, breast, colorectal, and gastric).

Craif USA was established in 2023 to introduce this platform to the US market, with a focus on pancreatic cancer. They are currently enrolling cancer patients and high-risk controls for US population validation of the assay. Craif USA is also developing a portfolio strategy tailored to the unmet clinical needs and competitive landscape of the US.

Notable Achievements

  • Raised over US$33 million including equity, debt and grants
  • Launched miSignal", a multiple early cancer detection test in Japan, with annual sales growth of 500-600%
  • Pancreatic cancer clinical trial for PMDA (equivalent to FDA) approval to start in 2024

Currently Operating in One Region

Press Mentions

May 23, 2024

Unreasonable Impact announces new roster of ventures for Asia Pacific programme

Read on Unreasonable »

More Ventures in Health

Get the Unreasonable Newsletter

Get monthly updates on Craif and over 396 other ventures working to solve the world's toughest problems.

Read our Privacy Policy.